Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines

Michael B. Streiff, Bjorn Holmstrom, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, Charles Eby, John Fanikos, Randolph B. Fenninger, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Paul Hendrie, Nicole Kuderer, Alfred Lee, Jason T. Lee, Mirjana Lovrincevic, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Rita PaschalSanford Shattil, Tanya Siddiqi, Kristi J. Smock, Gerald Soff, Tzu Fei Wang, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, Anita M. Engh

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

Original languageEnglish (US)
Pages (from-to)1079-1095
Number of pages17
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Guidelines
Venous Thromboembolism
Neoplasms
Obesity
Ambulatory Care
Blood Volume
Anticoagulants
Inpatients
Body Weight
Morbidity
Mortality
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Cancer-associated venous thromboembolic disease, version 1.2015 : Featured updates to the NCCN Guidelines. / Streiff, Michael B.; Holmstrom, Bjorn; Ashrani, Aneel; Bockenstedt, Paula L.; Chesney, Carolyn; Eby, Charles; Fanikos, John; Fenninger, Randolph B.; Fogerty, Annemarie E.; Gao, Shuwei; Goldhaber, Samuel Z.; Hendrie, Paul; Kuderer, Nicole; Lee, Alfred; Lee, Jason T.; Lovrincevic, Mirjana; Millenson, Michael M.; Neff, Anne T.; Ortel, Thomas L.; Paschal, Rita; Shattil, Sanford; Siddiqi, Tanya; Smock, Kristi J.; Soff, Gerald; Wang, Tzu Fei; Yee, Gary C.; Zakarija, Anaadriana; McMillian, Nicole; Engh, Anita M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 9, 01.09.2015, p. 1079-1095.

Research output: Contribution to journalArticle

Streiff, MB, Holmstrom, B, Ashrani, A, Bockenstedt, PL, Chesney, C, Eby, C, Fanikos, J, Fenninger, RB, Fogerty, AE, Gao, S, Goldhaber, SZ, Hendrie, P, Kuderer, N, Lee, A, Lee, JT, Lovrincevic, M, Millenson, MM, Neff, AT, Ortel, TL, Paschal, R, Shattil, S, Siddiqi, T, Smock, KJ, Soff, G, Wang, TF, Yee, GC, Zakarija, A, McMillian, N & Engh, AM 2015, 'Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 9, pp. 1079-1095. https://doi.org/10.6004/jnccn.2015.0133
Streiff, Michael B. ; Holmstrom, Bjorn ; Ashrani, Aneel ; Bockenstedt, Paula L. ; Chesney, Carolyn ; Eby, Charles ; Fanikos, John ; Fenninger, Randolph B. ; Fogerty, Annemarie E. ; Gao, Shuwei ; Goldhaber, Samuel Z. ; Hendrie, Paul ; Kuderer, Nicole ; Lee, Alfred ; Lee, Jason T. ; Lovrincevic, Mirjana ; Millenson, Michael M. ; Neff, Anne T. ; Ortel, Thomas L. ; Paschal, Rita ; Shattil, Sanford ; Siddiqi, Tanya ; Smock, Kristi J. ; Soff, Gerald ; Wang, Tzu Fei ; Yee, Gary C. ; Zakarija, Anaadriana ; McMillian, Nicole ; Engh, Anita M. / Cancer-associated venous thromboembolic disease, version 1.2015 : Featured updates to the NCCN Guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 9. pp. 1079-1095.
@article{8d0c990f47744751849ffabb7986a735,
title = "Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines",
abstract = "The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.",
author = "Streiff, {Michael B.} and Bjorn Holmstrom and Aneel Ashrani and Bockenstedt, {Paula L.} and Carolyn Chesney and Charles Eby and John Fanikos and Fenninger, {Randolph B.} and Fogerty, {Annemarie E.} and Shuwei Gao and Goldhaber, {Samuel Z.} and Paul Hendrie and Nicole Kuderer and Alfred Lee and Lee, {Jason T.} and Mirjana Lovrincevic and Millenson, {Michael M.} and Neff, {Anne T.} and Ortel, {Thomas L.} and Rita Paschal and Sanford Shattil and Tanya Siddiqi and Smock, {Kristi J.} and Gerald Soff and Wang, {Tzu Fei} and Yee, {Gary C.} and Anaadriana Zakarija and Nicole McMillian and Engh, {Anita M.}",
year = "2015",
month = "9",
day = "1",
doi = "10.6004/jnccn.2015.0133",
language = "English (US)",
volume = "13",
pages = "1079--1095",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Cancer-associated venous thromboembolic disease, version 1.2015

T2 - Featured updates to the NCCN Guidelines

AU - Streiff, Michael B.

AU - Holmstrom, Bjorn

AU - Ashrani, Aneel

AU - Bockenstedt, Paula L.

AU - Chesney, Carolyn

AU - Eby, Charles

AU - Fanikos, John

AU - Fenninger, Randolph B.

AU - Fogerty, Annemarie E.

AU - Gao, Shuwei

AU - Goldhaber, Samuel Z.

AU - Hendrie, Paul

AU - Kuderer, Nicole

AU - Lee, Alfred

AU - Lee, Jason T.

AU - Lovrincevic, Mirjana

AU - Millenson, Michael M.

AU - Neff, Anne T.

AU - Ortel, Thomas L.

AU - Paschal, Rita

AU - Shattil, Sanford

AU - Siddiqi, Tanya

AU - Smock, Kristi J.

AU - Soff, Gerald

AU - Wang, Tzu Fei

AU - Yee, Gary C.

AU - Zakarija, Anaadriana

AU - McMillian, Nicole

AU - Engh, Anita M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

AB - The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=84941770097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941770097&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0133

DO - 10.6004/jnccn.2015.0133

M3 - Article

C2 - 26358792

AN - SCOPUS:84941770097

VL - 13

SP - 1079

EP - 1095

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -